Biomarin Pharmaceutical (BMRN) Cost of Revenue (2009 - 2026)

Biomarin Pharmaceutical has disclosed Cost of Revenue across 18 years of filings, most recently posting $195.0 million for Q1 2026.

• Quarterly Cost of Revenue rose 28.66% year-over-year to $195.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $760.9 million (up 25.43% YoY) and the FY2025 annual result came in at $717.4 million, up 23.65% from the prior year.
• Cost of Revenue slipped to $195.0 million in Q1 2026, from $275.7 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $275.7 million in Q4 2025 and troughed at $116.3 million in Q3 2022.
• A 5-year average of $148.7 million and a median of $136.1 million in 2024 frame the typical range for Cost of Revenue.
• Biggest YoY gain for Cost of Revenue was 102.52% in 2025; the steepest drop was 25.67% in 2025.
• Tracing BMRN's Cost of Revenue over 5 years: stood at $146.6 million in 2022, then dropped by 5.94% to $137.9 million in 2023, then slipped by 1.3% to $136.1 million in 2024, then surged by 102.52% to $275.7 million in 2025, then declined by 29.27% to $195.0 million in 2026.
• Business Quant data shows BMRN's Cost of Revenue at $195.0 million in Q1 2026, $275.7 million in Q4 2025, and $140.1 million in Q3 2025.